150 related articles for article (PubMed ID: 2859077)
21. General anesthesia in a patient on long-term amphetamine therapy: is there cause for concern?
Fischer SP; Healzer JM; Brook MW; Brock-Utne JG
Anesth Analg; 2000 Sep; 91(3):758-9. PubMed ID: 10960415
[TBL] [Abstract][Full Text] [Related]
22. [Treatment of excessive daytime sleepiness].
Sonka K
Ceska Slov Psychiatr; 1996 May; 92 Suppl 1():15-22. PubMed ID: 8768941
[TBL] [Abstract][Full Text] [Related]
23. Effects of mazindol in two patients with Prader-Willi syndrome.
Itoh M; Koeda T; Ohno K; Takeshita K
Pediatr Neurol; 1995 Nov; 13(4):349-51. PubMed ID: 8771175
[TBL] [Abstract][Full Text] [Related]
24. Mazindol (Teronac)- another anorectic drug.
Drug Ther Bull; 1974 Dec; 12(26):101-2. PubMed ID: 4459058
[No Abstract] [Full Text] [Related]
25. [Clinical evaluation of Teronac (mazindol) in the treatment of obesity in children. Part II. Anorectic properties and side effects (author's transl)].
Gołebiowska M; Chlebna-Sokół D; Kobierska I; Konopińska A; Małek M; Mastalska A; Zwaigzne-Raczyńska J
Przegl Lek; 1981; 38(3):355-8. PubMed ID: 7017827
[No Abstract] [Full Text] [Related]
26. [Clinical use of mazindol in the treatment of essential obesity].
Guazzelli R; Piazzini M; Conti C; Papi L; Strazzulla G; Matassi L
Clin Ter; 1987 Mar; 120(5):385-91. PubMed ID: 2953538
[No Abstract] [Full Text] [Related]
27. [Overweight as a therapeutic problem. Experience with the appetite depressant Mazindol].
Linke H
Med Welt; 1976 Oct; 27(42):2021-5. PubMed ID: 792620
[No Abstract] [Full Text] [Related]
28. Mazindol for nocturnal enuresis.
Tiptaft RC; Woodhouse CR; Badenoch DF
Br J Urol; 1984 Dec; 56(6):641-3. PubMed ID: 6534482
[TBL] [Abstract][Full Text] [Related]
29. Double-blind evaluation of mazindol in refractory obesity.
Smith RG; Innes JA; Munro JF
Br Med J; 1975 Aug; 3(5978):284. PubMed ID: 1097046
[No Abstract] [Full Text] [Related]
30. The effect of mazindol on growth hormone secretion in boys with Duchenne muscular dystrophy.
Coakley JH; Moorcraft J; Hipkin LJ; Smith CS; Griffiths RD; Edwards RH
J Neurol Neurosurg Psychiatry; 1988 Dec; 51(12):1551-7. PubMed ID: 3221222
[TBL] [Abstract][Full Text] [Related]
31. [Falling sleep inopportunely: treatment of narcolepsy].
Guerrero IL; Sander C
MMW Fortschr Med; 2008 Dec; 150(51-52):35-7. PubMed ID: 19156954
[No Abstract] [Full Text] [Related]
32. A Double-Blind, Placebo-Controlled, Phase II Study to Determine the Efficacy, Safety, Tolerability and Pharmacokinetics of a Controlled Release (CR) Formulation of Mazindol in Adults with DSM-5 Attention-Deficit/Hyperactivity Disorder (ADHD).
Wigal TL; Newcorn JH; Handal N; Wigal SB; Mulligan I; Schmith V; Konofal E
CNS Drugs; 2018 Mar; 32(3):289-301. PubMed ID: 29557078
[TBL] [Abstract][Full Text] [Related]
33. The effect of an anorectic agent (Mazindol) on control of obese diabetics.
Sanders M; Breidahl H
Med J Aust; 1976 Oct; 2(15):576-7. PubMed ID: 994969
[TBL] [Abstract][Full Text] [Related]
34. AN 448 Sandoz (Mazindol) in the treatment of obesity.
Wallace AG
Med J Aust; 1976 Mar; 1(11):343-5. PubMed ID: 775265
[TBL] [Abstract][Full Text] [Related]
35. [Mazindol: a new anorectic drug].
Siani V
Clin Ter; 1978 Jan; 84(1):100-1. PubMed ID: 630811
[No Abstract] [Full Text] [Related]
36. Effect of modafinil on fatigue, mood, and health-related quality of life in patients with narcolepsy.
Becker PM; Schwartz JR; Feldman NT; Hughes RJ
Psychopharmacology (Berl); 2004 Jan; 171(2):133-9. PubMed ID: 14647965
[TBL] [Abstract][Full Text] [Related]
37. Amphetamines and narcolepsy: use of the Stanford database.
Guilleminault C
Sleep; 1993 Apr; 16(3):199-201. PubMed ID: 8506450
[No Abstract] [Full Text] [Related]
38. [Clinical trial with a nonamphetaminic anoretic].
Campagnoli M
Rev Iber Endocrinol; 1976; 23(137):463-83. PubMed ID: 794978
[TBL] [Abstract][Full Text] [Related]
39. Salivary secretions: narcolepsy and central nervous system stimulants.
Nordgarden H; Lamkin M; Oppenheim FG; Storhaug K; Jensen JL
J Dent Res; 1998 Oct; 77(10):1817-22. PubMed ID: 9786638
[TBL] [Abstract][Full Text] [Related]
40. Double-blind evaluation of the effects of mazindol on pain, depression, anxiety, appetite, and activity in terminal cancer patients.
Bruera E; Carraro S; Roca E; Barugel M; Chacon R
Cancer Treat Rep; 1986 Feb; 70(2):295-8. PubMed ID: 3512080
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
